26 results about "Meningitis" patented technology

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

Use of an NLRP3 inhibitor for treating encephalitis or meningitis. Specifically, provided is use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating encephalitis or meningitis, wherein each substituent is as defined in the description.

The application discloses a novel group B meningococcal outer membrane protein bifunctional carrier, relates to the technical field of biopharmaceutical processes, and discloses a group B meningococcal outer membrane protein bifunctional carrier and application of the bifunctional carrier in a meningitis combined vaccine. The bifunctional carrier is human H factor binding protein fHbp, and comprises two kinds of recombinant proteins BA and BB, and the amino acid sequences of the two kinds of recombinin proteins are SEQ ID No. 62 and SEQ ID No. 63 respectively. The BA protein is coupled with group A capsule polysaccharide to form a group A combined vaccine, the BB protein is coupled with group C capsule polysaccharide to form a group C combined vaccine, and the two are mixed to form a group ABC triple vaccine. Each dose of the triple vaccine contains 40 μg of group A / C polysaccharide, 160 μg of BA / BB protein in total and 1.0 mg of aluminum adjuvant. The BA and BB proteins are expressed by E. coli, are broken by high-pressure homogenization, and are purified by anion exchange chromatography, and the purity is greater than or equal to 95%. The triple vaccine can simultaneously induce immune responses to groups A, B and C of meningitis, the serum bactericidal titer is greater than or equal to 1:32 after primary immunization, and the titer is maintained for more than 56 days after three immunizations.

The invention relates to a polymer with a side chain containing biguanidyl as well as a preparation method and application of the polymer. The polymer has efficient antibacterial activity and / or anti-tumor activity, can penetrate the blood brain barrier, has application potential in treatment of meningitis and / or brain tumor and other diseases, and has excellent application prospects in the fields of drug delivery, drug synergy, drug modification, gene delivery and the like.

The invention belongs to the technical field of machine learning auxiliary diagnosis, and particularly relates to a meningitis rapid diagnosis system based on the combination of an SERS technology and a machine learning method. The system comprises: an input module, which is used for inputting SERS spectral data of cerebrospinal fluid; the preprocessing module is used for preprocessing the SERS spectrum data; and the prediction module is used for calculating the preprocessed SERS spectral data through a machine learning model to obtain a meningitis classification prediction result. According to the method and the system, the SERS technology and the machine learning method are combined for the first time, the method and the system for rapidly and automatically diagnosing the meningitis are realized, and the method and the system have the advantages of simplicity, rapidness, accuracy, capability of carrying out subtype classification and the like, and have a good application prospect in clinical diagnosis of the meningitis, particularly in an early screening process.

The invention relates to the technical field of biological detection, and discloses a composition for detecting meningitis pathogens, a kit and application. The composition comprises detection primers and selectable probes for 14 pathogens causing meningitis, multiple pathogens can be detected at the same time through the multiple PCR technology, the use amount of samples is reduced, and meanwhile the composition has the advantages of being high in detection speed, efficiency, accuracy and sensitivity and the like.

The application discloses a novel diterpenoid compound with anti-inflammatory activity separated from Origanum vulgare Linn. 20 H 18 O4, and a structural formula is as shown in formula I. A preparation method of the compound comprises the following steps: crushing dried medicinal materials of Origanum vulgare Linn., extracting by using ethanol, concentrating under reduced pressure to obtain total extract; after extraction by using petroleum ether, the target compound is obtained through silica gel column chromatography, Sephadex LH-20 gel column chromatography and preparation type high performance liquid phase chromatography separation and purification. In vitro anti-inflammatory experiments show that the compound can significantly inhibit NO generation in a LPS-induced RAW264.7 macrophage model, and the inhibition rate reaches 62.97%, and the compound shows good anti-inflammatory activity. The compound can be used for preparing medicines for preventing or treating inflammatory diseases such as enteritis, hepatitis and meningitis.

The invention provides quantum dot modified group B neisseria meningitidis and a preparation method of a vaccine of the quantum dot modified group B neisseria meningitidis. The preparation method comprises the following steps: taking corn straws and sunflower straws as a straw mixture according to a weight ratio of (1-1.5): 1, putting the straw mixture, an escherichia coli DH5alpha cell membrane and urea into water according to a weight ratio of 100: 100: 1, carrying out high-temperature heating reaction, and filtering and dialyzing reactants to prepare aminated quantum dots; extruding the aminated quantum dots and a group B neisseria meningitidis cell membrane through a liposome extruder according to a weight ratio of (8-10): 1, and centrifuging to obtain cell membrane hybrid aminated quantum dots; and co-incubating the cell membrane hybrid aminated quantum dots and the group B neisseria meningitidis to obtain the cell membrane hybrid aminated quantum dots. The group B neisseria meningitidis is modified by adopting the specific quantum dots, the toxicity of the modified group B neisseria meningitidis is obviously reduced, and the modified group B neisseria meningitidis is expected to be applied to related fields of vaccines and the like.

A method of treating a patient with a complement-associated disorder with a complement inhibitor and then monitoring the patient during administration of the complement inhibitor and thereafter. The method includes certifying a prescriber and a dispenser and then monitoring the patient during and after administration of the complement inhibitor for an adverse event, including a meningococcal or pneumococcal event.

The present invention provides a method and system for processing multiple meningitis data using a machine learning-assisted sensor array, belonging to the field of data processing and sensor array technology. The present invention comprises obtaining a sensor element; synthesizing the sensor element using a metal-organic framework, a covalent organic framework, and a hydrogen-bonded organic framework; constructing a sensor array based on the sensor element; obtaining a fluorescence signal based on the sensor array and meningitis cerebrospinal fluid; and obtaining information on the type of meningitis based on the fluorescence signal and a machine learning algorithm. The present invention enables data processing for different types of meningitis infections.

The invention discloses an accurate auxiliary meningitis typing method based on a machine learning model, electronic equipment and a storage medium, and the method comprises the steps: selecting medical detection items as features, and combining the features to construct a feature subset; constructing a meningitis subdivision discrimination framework, and disassembling meningitis diagnosis requirements into nine mutually independent binary discrimination tasks; taking the feature subset as input, executing each binary discrimination task to construct a training task, and training an independent machine learning model; obtaining a binary discrimination task selected by a doctor and a binary discrimination task selected by the doctor; and respectively calling independent machine learning models for execution, and outputting auxiliary typing discrimination. According to the accurate meningitis typing method based on multi-task discrimination of the machine learning model, clinicians are helped to judge meningitis categories by using a machine learning method, so that accurate and effective diagnosis and treatment are provided for patients in time.

The invention discloses a method for establishing a model for inflammation of mouse brain microvascular endothelial cells infected by haemophilus parasuis, which is used for simulating the process of porcine meningitis caused by haemophilus parasuis infection by using the mouse brain microvascular endothelial cells infected by haemophilus parasuis and researching the pathogenesis of the porcine meningitis caused by haemophilus parasuis. The optimal MOI of mouse brain microvascular endothelial cells infected by haemophilus parasuis is 1, the optimal infection time is 6 h, under the condition, the inflammatory factor level of the cells is remarkably increased, and the success rate of the cell inflammation model construction method is higher.

This invention discloses a serogroup B meningococcal vaccine and its application. The serogroup B meningococcal vaccine contains one or more recombinant proteins with amino acid sequences as shown in SEQ ID NO:1-7. The vaccine against serogroup B meningococcus of this invention induces a strong humoral immune response and broad-spectrum protective efficacy. Compared with existing technologies, the vaccine against serogroup B meningococcus of this invention has high antibody titers and broad protective efficacy. It has broad application value and positive social benefits in preventing diseases caused by serogroup B meningococcus infection and alleviating severe cases.

The invention discloses a group B meningococcus vaccine composition as well as a preparation method and application thereof. The vaccine composition comprises a factor H binding protein (fHbp) fusion protein and an outer membrane vesicle (OMV) wherein the factor H binding protein fusion protein comprises a meningococcal heparin binding protein antigen (NHBA) or a variant thereof, and an operably linked fHbp or a variant thereof. The vaccine composition can induce an organism to generate a functional antibody with bactericidal activity, has bactericidal activity on three variant strains, can induce the organism to generate higher protective response, and improves the bactericidal coverage rate of the vaccine on domestic B group strains.

Provided is a composition for detecting multiple encephalitis / meningitis / respiratory pathogens. The composition includes primer sequences for the pathogens as shown in SEQ ID NOs: 1-7, 9-23 and 25-32, in which SEQ ID NOs: 1-7 and 9-16 carry fluorescent reporter groups. In addition, the present invention further provides a use of the foregoing composition in the preparation of a kit, and a related kit and a method for using the same.

The present invention relates to the technical field of MenB vaccines, and specifically to a self-replicating mRNA sequence, a vaccine for preventing MenB, and a method for preparing the same. A self-replicating mRNA sequence comprises RNA encoding a region in an amino acid sequence, wherein the amino acid sequence comprises a single sequence shown in SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10, which is concatenated in any order to form a tandem sequence. The present application screens amino acid sequences for strains found in China's monitoring coverage, provides a vaccine for preventing MenB, and reduces the mortality rate caused by meningococcal B infection in China. The vaccine for preventing MenB provided by the present application has a low number of injection needles, a low dose, and a high expression effect, which can reduce the dosage and frequency of administration, while improving the expression efficiency of the vaccine, in order to achieve a better immune effect.

The invention discloses an application of an acetylcholine receptor stimulant in treatment of meningitis. It is found for the first time that the acetylcholine receptor stimulant GTS-21 can prevent and treat meningitis and can also prevent and treat cognitive impairment caused by meningitis, a new thought is provided for effective treatment of meningitis and memory impairment caused by meningitis, and the acetylcholine receptor stimulant GTS-21 has wide application prospects.

The invention discloses a brain targeting peptide and application thereof in preparation of a drug delivery system, and belongs to the technical field of biological medicine. The polypeptide with brain targeting is obtained through a phage display technology, the drug delivery system prepared from the polypeptide can more accurately deliver drugs to brain disease positions, and accurate and effective diagnosis and treatment of brain diseases are achieved. Specifically, the invention discloses a vancomycin-loaded nano-micelle, and confirms that brain-targeted peptide modified on the surface of the micelle can remarkably improve the blood brain barrier crossing capacity of a drug in vitro and in vivo, has high targeting property on the brain of a mouse, and shows a remarkable treatment effect in mouse meningitis model treatment.

The present disclosure provides a method of identifying and / or quantifying a perceived immune fitness of an individual. The method comprises identifying a frequency and / or a severity of one or more conditions experienced by an individual. The one or more conditions includes sore throat, headaches, flu, runny nose, coughing, cold sores, boils, mild fever, warts, pneumonia, bronchitis, sinusitis, sudden high fever, ear infection, diarrhea, meningitis, eye infection, sepsis, long healing injuries, shortness of breath, skin problems, muscle and joint pain, and common cold. The method further includes calculating a perceived immune fitness score of the individual based on up to 10 of the one or more conditions with the highest frequency and / or severity.

The invention discloses a novel diterpenoid compound which is separated from origanum vulgare and has anti-inflammatory activity, the molecular formula of the diterpenoid compound is C20H18O4, and the structural formula of the diterpenoid compound is shown as a formula I. The preparation method of the compound comprises the following steps: crushing a dried medicinal material of origanum vulgare, extracting with ethanol, and concentrating under reduced pressure to obtain a total extract; and after extracting with petroleum ether, separating and purifying through silica gel column chromatography, Sephadex LH-20 gel column chromatography and preparative high performance liquid chromatography to obtain a target compound. In-vitro anti-inflammatory experiments show that the compound can significantly inhibit NO generation in an LPS-induced RAW264.7 macrophage model, the inhibition rate reaches 62.97%, and good anti-inflammatory activity is shown. The compound can be used for preparing medicines for preventing or treating inflammatory diseases such as enteritis, hepatitis and meningitis.

This application relates to the technical field of vaccine conjugates, specifically to a method for preparing a polysaccharide conjugate of group A meningococcal capsular polysaccharide, including the preparation of polysaccharide derivatives, mixing ratio, conjugation reaction, aging treatment, ultrafiltration and sterilization steps. This application eliminates the pH adjustment and conjugate purification steps in the activation process by optimizing the process parameters, but the quality of the harvested polysaccharide conjugate still meets the national standards, thereby simplifying the preparation process of polysaccharide conjugates and shortening the preparation cycle of polysaccharide conjugates.

The present invention belongs to the field of biomedical technologies, and particularly relates to a broad-spectrum multi-subunit vaccine for preventing Neisseria meningitidis serogroup B infection and its uses, including complement factor H-binding protein fHbp; Neisseria heparin-binding antigen NHBA; pile protein; a chimeric antigen obtained by removing the signal peptide part of complement factor H-binding protein fHbp as a backbone and fusing and expressing it with the variable region of an additional antigen Opa; App protein; IgA protease; and adjuvant CpG. The vaccine in the present invention is highly efficient, broad-spectrum and low-cost. At the same time, the vaccine adopts the route of mucosal immunity, has no tissue damage, no local side effects and is easy to use, and is easy to promote.

The present invention discloses a system and method for the targeted detection of magnetic resonance signals of glucose and lactate molecules in cerebrospinal fluid based on J-editing spectroscopy, which belongs to the field of magnetic resonance medicine technology. The present invention realizes the accurate detection of magnetic resonance signals of α-glucose and lactose in cerebrospinal fluid by precisely manipulating the quantum states of glucose and lactate molecules based on J-editing technology. The method of the present invention can measure the magnetic resonance signals of α-glucose and lactose molecules in the human brain rapidly, non-invasively and without radiation. The obtained data information has important application value in the early diagnosis, treatment monitoring and other aspects of diseases such as mitochondrial encephalomyopathy, meningitis and Alzheimer's disease.

An explainable artificial intelligence system for early prediction of missed severe diagnoses in intensive care unit patients is provided. The system comprises a data processing module configured to receive and process electronic health record data including patient demographics, vital signs, laboratory results, and diagnostic codes. A machine learning module with ensemble, deep learning, and large language models analyzes processed data to predict likelihood of severe diagnoses including acute myocardial infarction, acute pulmonary embolism, bacterial pneumonia, aortic dissection, meningitis, spinal abscess, bacterial endocarditis, and arterial thromboembolism. An explainability module generates feature importance rankings and provides interpretable explanations for predictions.